Prognostic value of depression and anxiety on breast cancer recurrence and mortality: a systematic review and meta-analysis of 282,203 patients.
Wang X, Wang N, Zhong L, Wang S, Zheng Y, Yang B, Zhang J, Lin Y, Wang Z. · 2020
Read Prognostic value of depression and anxiety on breast cancer recurrence and mortality: a systematic review and meta-analysis of 282,203 patients. by Wang X, Wang N, Zhong L, Wang S, Zheng Y, Yang B, Zhang J, Lin Y, Wang Z. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7714689.txt.
Introduction
Wang and co-authors pool studies on mood and breast cancer outcomes. Depression and anxiety are common in women with breast cancer. Whether they worsen the disease course was unclear. The team searched the literature for studies that tracked recurrence and death.
They kept 17 studies with 282,203 patients in total. Depression linked to higher recurrence and to higher death from all causes and from cancer. Anxiety linked to recurrence and to all-cause death, but not to cancer death. Both together raised death rates most. The authors urge care plans that treat mood as part of cancer care, not as a side issue.
Catalog record
| CREATOR | Wang X, Wang N, Zhong L, Wang S, Zheng Y, Yang B, Zhang J, Lin Y, Wang Z. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Prognostic value of depression and anxiety on breast cancer recurrence and mortality: a systematic review and meta-analysis of 282,203 patients By Xuan Wang, Neng Wang, Lidan Zhong, Shengqi Wang, Yifeng Zheng, Bowen Yang, Juping Zhang, Yi Lin, Zhiyu Wang Published in: Molecular Psychiatry DOI: 10.1038/s41380-020-00865-6 ABSTRACT Abstract Depression and anxiety are common comorbidities in breast cancer patients. Whether depression and anxiety are associated with breast cancer progression or mortality is unclear. Herein, based on a systematic literature search, 17 eligible studies involving 282,203 breast cancer patients were included. The results showed that depression was associated with cancer recurrence [1.24 (1.07, 1.43)], all-cause mortality [1.30 (1.23, 1.36)], and cancer-specific mortality [1.29 (1.11, 1.49)]. However, anxiety was associated with recurrence [1.17 (1.02, 1.34)] and all-cause mortality [1.13 (1.07, 1.19)] but not with cancer-specific mortality [1.05 (0.82, 1.35)]. Comorbidity of depression and anxiety is associated with all-cause mortality [1.34 (1.24, 1.45)] and cancer-specific mortality [1.45 (1.11, 1.90)]. Subgroup analyses demonstrated that clinically diagnosed depression and anxiety, being female and of younger age (<60 years), and shorter follow-up duration (≤5 years) were related to a poorer prognosis. Our study highlights the critical role of depression/anxiety as an independent factor in predicting breast cancer recurrence and survival. Further research should focus on a favorable strategy that works best to improve outcomes among breast cancer patients with mental disorders. Subject terms: Depression, Psychology INTRODUCTION Breast cancer is one of the most prevalent cancers as well as the leading cause of death among women. According to the WHO statistics from 2018, breast cancer has an incidence of 11.6% among all types of cancer, accounting for 6.5% of mortalities worldwide [1]. The survival rate of breast cancer patients in developed countries has improved in recent decades due to the advances in early screening and treatment [2]. However, the mortality rate of breast cancer patients in some developing countries remains high due to inefficient screening and treatment, leaving an overall high death toll worldwide [3]. Recurrence and metastasis are the main causes of death in breast cancer. In addition, cardiovascular complications in breast cancer survivors were identified as another important cause of death among these women [4, 5]. Therefore, in order to improve the prognosis and overall survival, it is important to identify the risk factors influencing breast cancer-related death. A number of factors can affect breast cancer progression and mortality. Recent studies have shown that the status of lymph nodes, tumor size, and histological subtypes are important risk factors determining its clinical outcomes [6–8]. In addition, clinical studies have demonstrated that demographic characteristics and lifestyle factors, such as age, obesity, smoking, and estrogen application, are also significantly related to breast cancer onset and development [9–13]. Importantly, with the transformation from the traditional medical system to a biopsychosocial medical network, much more attention has been paid to the role of psychological factors in the etiology and prognosis of breast cancer. The diagnosis and treatment of breast cancer are frequently accompanied by changes in physical status and function, unpleasant side effects, decline in quality of life, and impaired social relationships [14, 15]. Therefore, breast cancer patients always suffer from negative emotions under chronic psychological stress. Clinical studies have also suggested that patients with breast cancer suffer a much higher prevalence of mental disorders compared with the general population. Depression and anxiety are the two most common psychiatric symptoms. Results from previous meta-analyses revealed that the prevalence of depression and anxiety among breast cancer patients was up to 32.2% and 41.9%, respectively [16, 17]. Depression and anxiety can affect the physiological function, treatment compliance, psychological function, and quality of life of patients with breast cancer and may even be an important factor affecting the mortality of breast cancer patients. Although whether psychological factors predict breast cancer mortality has been widely investigated, the findings are not consistent. Seven studies reported that depression was associated with an increase in the risk of mortality [18–24]. Another six studies found no association between depression and mortality [25–30]. Previous meta-analyses presented evidence that depression was related to mortality [31, 32] but not to progression in cancer patients [32]. However, these meta-analyses were constrained by high heterogeneity based on mixed types of cancers. Furthermore, as breast cancer is a hormone-dependent neoplasm, its response to mental illness may be distinct from that of other cancers. Meanwhile, several studies have assessed whether improvements in depression are associated with survival benefits. Giese-Davis et al. [33] found that a decrease in depression under supportive-expressive group therapy (SEGT) predicted longer survival for women with breast cancer. A recent meta-analysis also found that SEGT and other supportive psychotherapeutic interventions did improve overall cancer survival [34], while Kissane et al. [35] found no evidence that SEGT prolongs survival. With regard to anxiety, its influence on breast cancer prognosis is still under dispute. Shim et al. [24] found that anxiety is predictive of all-cause mortality for breast cancer patients. Groenvold et al. [27] demonstrated that anxiety was associated with relapse-free survival, but not with overall survival. However, several studies indicated that no association was found between anxiety and mortality in breast cancer patients [21, 23, 25, 28, 36]. Notably, animal models have clearly shown that chronic psychological stress can promote tumor growth and lung metastasis [37, 38]. Thaker et al. [39] found that chronic stress promotes ovarian tumor growth and angiogenesis in a murine model, and that adrenergic blockade reverses the effect. Hence, it is necessary to conduct comprehensive and rigorous studies to determine the relationship between depression and anxiety and breast cancer survival and progression. Herein, we conducted a meta-analysis of depression and anxiety in relation to mortality and progression in patients with breast cancer. We collected and quantitatively integrated the data regarding the association between recurrence, all-cause mortality and cancer-specific mortality with depression and anxiety, respectively. The results demonstrate that depression and anxiety are both associated with recurrence and all-cause mortality. Furthermore, depression and comorbid depression and anxiety are related to cancer-specific mortality, while anxiety alone is not. Our findings highlight the importance of depression and anxiety in predicting breast cancer prognosis and suggest that careful consideration should be given to routine screening for mental distress in breast cancer patients. METHODS Protocol and guidance This study was performed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analysis. The protocol for this review has been registered at PROSPERO (CRD42020162466). Search strategy Following recommendations of the Meta-analysis of Observational Studies in Epidemiology group [40], we searched the following electronic databases for studies written in English from their inception until December 15, 2019: PubMed, Embase, The Cochrane Library, and PsycINFO. The search strategy was implemented using combined index terms (Medical Subject Headings, Emtree) and free-text keywords. Keywords included (“breast cancer” OR “breast neoplasm”) AND (“depression” OR “anxiety”) AND (“survival” OR “mortality” OR “metastasis” OR “recurrence”). Tables S1–S4 in the supplementary show the detailed methods used for searching all of the databases. Additional studies were searched by examining the reference lists of reviews and eligible publications for potentially eligible studies. Inclusion and exclusion criteria The retrieved studies were eligible for qualitative and quantitative analysis if they (1) were cohort studies, (2) investigated patients with breast cancer, (3) assessed depression or anxiety by standard diagnostic criteria